EU/3/19/2195

About

On 21 August 2019, orphan designation EU/3/19/2195 was granted by the European Commission to Anavex Germany GmbH, Germany, for 1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride (also known as ANAVEX2-73) for the treatment of Rett syndrome.

Key facts

Active substance
1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride
Disease / condition
Treatment of Rett syndrome
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2195

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Anavex Germany GmbH
Am Klopferspitz 19a
82152 Planegg
Germany
Tel: +49 (0) 89 71669059
E-mail: rett@anavex.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating